Fluorescently labeled bevacizumab in human breast cancer: defining the classification threshold

Maximilian Koch(Helmholtz Munich), Vasilis Ntziachristos(Helmholtz Zentrum München), Annelies Jorritsma‐Smit(The Netherlands Cancer Institute), Wouter B. Nagengast(University Medical Center Groningen), Matthijs D. Linssen(The Netherlands Cancer Institute), Gooitzen M. van Dam(Polpharma Biologics (Netherlands)), Liesbeth Jansen(Dialyse Centrum Groningen), P. J. van Diest(University Medical Center Utrecht), Jürgen Glatz(Helmholtz Munich), Arjen J. Witkamp(University Medical Center Utrecht), Panagiotis Symvoulidis(Helmholtz Munich), Mariëtte E.G. Kranendonk(Princess Máxima Center), Willem P.Th.M. Mali(Utrecht University), Michaela Aichler(Helmholtz Zentrum München), Laetitia E. Lamberts(University Medical Center Groningen), Elisabeth G.E. de Vries(Karolinska University Hospital), Esther de Boer(University Medical Center Groningen), Axel Walch(Unknown), Sjoerd G. Elias(Utrecht University), Elsken van der Wall(University Medical Center Utrecht), Johannes S. de Jong(Utrecht University), Carolien P. Schröder(University Medical Center Groningen), P. Beatriz García-Allende(Helmholtz Munich), Anton G.T. Terwisscha van Scheltinga(University Medical Center Groningen), Marjolijn N. Lub–de Hooge(University Medical Center Groningen), Arthur L.L. Adams(Utrecht University), Jakob de Vries(Tilburg University), Sabrina Oliveira(Unknown), Bert van der Vegt(University Medical Center Groningen)

Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE

July 28, 2017

Cited by 0

Related Papers

|Nature Medicine|2003|1.9k

|Nature Biotechnology|2005|1.6k

|The Lancet Oncology|2015|1.1k

|European Radiology|2003|978

|Nature Medicine|2002|825